Alnylam Pharmaceuticals | ALNY - 债务



金融业
股票价格
USD
资产
USD 5.56B
现金及等价物
USD 1.71B
销售成本
USD 298.45M
流动资产
USD 4.62B
流动负债
USD 1.51B
债务
USD 1.27B
EBIT
USD 112.6M
EBITDA
USD 245.34M
员工
2.23K
EPS每股收益
USD 1.84
股本和储备
USD 1.35B
销售毛利
USD 992.69M
债务利息支出
USD 82.05M
利息收入
USD 26.6M
贷款资金
USD 2.47B
市值
USD 32.89B
净收入
USD 164.49M
营业费用
USD 1.06B
营业利润
USD 112.6M
普通股股本
USD 133.73M
PE价格收益
75.64
税前利润
USD 177.81M
销售收入
USD 1.29B
销售和管理费用
USD 347.92M
股票
USD 97.11M
贸易债权人
USD 108.02M
应收帐款人
USD 912.74M


债务 更改 日
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
Amgen USD 57.32B 2.72B 2026-03
Arrowhead Research USD 983.69M 5.77M 2026-06
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
Moderna USD 1.3B 7M 2026-03
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 14.98B 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 20.02B 1.73B 2026-03
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Takeda JPY 4.94T 58.13B 2026-06
Tectonic Therapeutic USD 876K 115K 2024-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06
Xencor USD 175.16M 12.58M 2026-03